2 active not recruiting, 2 unknown, 1 recruiting, 1 suspended. 5 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 2, Recruiting 1, Suspended 1, Unknown 1 |
| Phase 1 | 1 | Suspended 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Intravascular Large B-Cell Lymphoma: new trials by email Literature Review of Intravascular Large B-Cell Lymphoma trials Research Report on Intravascular Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma Cerebral Spinal Fluid ctDNA - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 50 | 2024-12-11 | 2025-12-18 |
| A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types No interventions need to be specified for this study - Lymphoma, Extranodal Lymphoma | Unknown | Ruijin Hospital | 10000 | 2023-07-01 | 2023-06-18 | |
| Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 422 | 2021-05-20 | 2026-11-12 |
| Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma Zanubrutinib, Rituximab, Cyclophosphamide - Intravascular Large B-Cell Lymphoma | Phase 2 | Unknown | Peking Union Medical College Hospital | 20 | 2021-04-01 | 2021-05-24 |
| Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas Nivolumab, Varlilumab - ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 54 | 2018-12-21 | 2026-11-16 |
| Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma Cyclophosphamide, Doxorubicin Hydrochloride, Nivolumab - Aggressive Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Suspended | Northwestern University | 30 | 2018-11-20 | 2022-08-15 |
Lymphoma, Large B-Cell, Diffuse (4) · Lymphoma, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2) · Burkitt Lymphoma (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Immunoblastic Lymphadenopathy (1) · Lymphoma (1) · Lymphoma, Extranodal NK-T-Cell (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, Primary Effusion (1) · Lymphomatoid Granulomatosis (1) · Plasmablastic Lymphoma (1)
Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Lymphatic Diseases (5) · Lymphoma, Non-Hodgkin (5) · Lymphoproliferative Disorders (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Lymphoma (4) · Lymphoma, B-Cell (3) · DNA Virus Infections (1) · Epstein-Barr Virus Infections (1) · Herpesviridae Infections (1) · Histiocytic Disorders, Malignant (1) · Histiocytosis (1)
Cyclophosphamide (3) · Prednisone (3) · Rituximab (3) · CT-P10 (2) · Doxorubicin (2) · Nivolumab (2) · Vincristine (2) · deltacortene (2) · prednylidene (2) · Azacitidine (1) · Disulfides (1) · Epirubicin (1) · Hyaluronoglucosaminidase (1) · Immunoglobulin G (1) · Magnetic Resonance Spectroscopy (1)
National Cancer Institute (NCI) (2) · Memorial Sloan Kettering Cancer Center (1) · Northwestern University (1) · Peking Union Medical College Hospital (1) · Ruijin Hospital (1)
United States (4) · China (2)
Daobin Zhou (1) · Elizabeth A Brem (1) · Jennifer Lue, MD (1) · Reem Karmali, MD (1) · Stephen M Ansell (1)
P30CA060553 (1), U10CA180888 (1), UM1CA186686 (1), UM1CA186709 (1)